MedPath

Extremely low gestational age infants' PARAcetamol Study

Phase 1
Conditions
Open ductus arteriosus of a premature infant
Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Registration Number
EUCTR2018-000566-11-FI
Lead Sponsor
niversity of Oulu
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

All extremely premature (born before 28 gestation weeks) or low birth weight (< 1000 g) infants treated in neonatal intensive care unit of Oulu University Hospital and who have an open ductus
Are the trial subjects under 18? yes
Number of subjects for this age range: 40
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

- Denial by the parents
- Severe congenital or chromosomal anomaly or severe clinical situation, that complicates the standard ductal therapies e.g. asphyxia, or persistent pulmonary hypertension of a newborn

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: To study the efficacy and safety of intravenous paracetamol in contracting ductus arteriosus of a very premature (<28 gestation weeks) or extremely low birth weight (<1000 g) infants ;Secondary Objective: Not applicable;Primary end point(s): Shortening of the ductal closure time;Timepoint(s) of evaluation of this end point: - after the study drug period<br>- at the discharge from the NIC
Secondary Outcome Measures
NameTimeMethod
Secondary end point(s): Cardiac ultrasound findings, ductal therapies, duration of the ventilation assist, paracetamol serum concentrations, possible paracetamol side effects, complications of prematurity, neonatal and long term morbidity and mortality ;Timepoint(s) of evaluation of this end point: - discharge to home
© Copyright 2025. All Rights Reserved by MedPath